zonisamide has been researched along with Nerve Degeneration in 4 studies
Zonisamide: A benzisoxazole and sulfonamide derivative that acts as a CALCIUM CHANNEL blocker. It is used primarily as an adjunctive antiepileptic agent for the treatment of PARTIAL SEIZURES, with or without secondary generalization.
zonisamide : A 1,2-benzoxazole compound having a sulfamoylmethyl substituent at the 3-position.
Nerve Degeneration: Loss of functional activity and trophic degeneration of nerve axons and their terminal arborizations following the destruction of their cells of origin or interruption of their continuity with these cells. The pathology is characteristic of neurodegenerative diseases. Often the process of nerve degeneration is studied in research on neuroanatomical localization and correlation of the neurophysiology of neural pathways.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The zonisamide-treated group received an intraperitoneal injection of zonisamide." | 5.40 | Zonisamide attenuates hyperoxia-induced apoptosis in the developing rat brain. ( Bayram, E; Karaoğlu, P; Kumral, A; Kurul, SH; Ozbal, S; Topçu, Y; Tuğyan, K; Yılmaz, O; Yiş, U, 2014) |
| " Chronic administration of zonisamide in Engrailed mutant mice was shown to improve the survival of nigrostriatal dopaminergic neurons compared with that under saline treatment." | 1.42 | Zonisamide reduces nigrostriatal dopaminergic neurodegeneration in a mouse genetic model of Parkinson's disease. ( Murata, M; Nambu, A; Sano, H, 2015) |
| "The zonisamide-treated group received an intraperitoneal injection of zonisamide." | 1.40 | Zonisamide attenuates hyperoxia-induced apoptosis in the developing rat brain. ( Bayram, E; Karaoğlu, P; Kumral, A; Kurul, SH; Ozbal, S; Topçu, Y; Tuğyan, K; Yılmaz, O; Yiş, U, 2014) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Topçu, Y | 1 |
| Bayram, E | 1 |
| Ozbal, S | 1 |
| Yiş, U | 1 |
| Tuğyan, K | 1 |
| Karaoğlu, P | 1 |
| Kumral, A | 1 |
| Yılmaz, O | 1 |
| Kurul, SH | 1 |
| Sano, H | 1 |
| Murata, M | 1 |
| Nambu, A | 1 |
| Yokoyama, H | 2 |
| Yano, R | 2 |
| Kuroiwa, H | 2 |
| Tsukada, T | 2 |
| Uchida, H | 2 |
| Kato, H | 2 |
| Kasahara, J | 2 |
| Araki, T | 2 |
4 other studies available for zonisamide and Nerve Degeneration
| Article | Year |
|---|---|
Zonisamide attenuates hyperoxia-induced apoptosis in the developing rat brain.
Topics: Animals; Animals, Newborn; Apoptosis; Brain; Disease Models, Animal; Hyperoxia; Immunohistochemistry | 2014 |
Zonisamide reduces nigrostriatal dopaminergic neurodegeneration in a mouse genetic model of Parkinson's disease.
Topics: Animals; Antioxidants; Antiparkinson Agents; Brain; Brain-Derived Neurotrophic Factor; Dopaminergic | 2015 |
Therapeutic effect of a novel anti-parkinsonian agent zonisamide against MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) neurotoxicity in mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antioxidants; Antiparkinson Agents; Disease M | 2010 |
Therapeutic effect of a novel anti-parkinsonian agent zonisamide against MPTP (1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine) neurotoxicity in mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antioxidants; Antiparkinson Agents; Disease M | 2010 |